MEDIA RELEASE PR36630
ADVANCE Reveals New Insights in the Fight Against Severe Diabetes Complications
MONTREAL, Oct. 16 /PRNewswire-AsiaNet/ --
New results from ADVANCE (Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial
ever performed in patients with type 2 diabetes worldwide, provide important
insights into the therapeutic strategy to adopt for efficient and safe blood
glucose control aimed at the reduction of severe diabetes complications.(1)
The new data from ADVANCE, presented today at the International Diabetes
Federation (IDF) Congress, show that the efficacy and safety of intensive
blood glucose control using gliclazide modified release (MR) (Diamicron
MR)-based regimen is maintained across a broad range of patients in different
clinical settings.(1)
ADVANCE demonstrated that intensive glucose control with a gliclazide
MR-based treatment regimen in people with type 2 diabetes reduces the
combined risk of microvascular and macrovascular events, primarily through
reductions in the risk of diabetic nephropathy.(2)
"Intensive glucose control with a gliclazide MR-based regimen was
effective in lowering HbA1C, irrespective of age, duration of diabetes, sex,
body mass index, or HbA1C at study entry, and also irrespective of initial
glucose lowering treatment," said ADVANCE Study Investigator Sophia Zoungas
from The George Institute for International Health, Australia. "The
gliclazide MR-based regimen was well-tolerated with very low rates of severe
hypoglycemia and no weight gain."
ADVANCE showed a positive trend toward a reduction of major
cardiovascular events in diabetes patients who received intensive glucose
control.(2) This finding was supported in a recent collaborative meta-
analysis of 4 trials of intensive glucose lowering, including ADVANCE and
ACCORD, which demonstrated a significant 9% reduction in major cardiovascular
events, primarily reflecting a 15% reduction in myocardial infarction.(3) On
the basis of observational data, several national registers (including more
than 70,000 patients with type 2 diabetes),have recently reported that
glucose lowering regimens that included gliclazide were associated with lower
risks of mortality compared to other therapeutic strategies.(4,5)
"ADVANCE is a huge reservoir of valuable clinical information," concluded
ADVANCE Principal Investigator Professor John Chalmers from The George
Institute for International Health, Australia. "For this reason, we plan to
continue the follow-up of the ADVANCE patients and we believe that this new
study-ADVANCE-ON(6)- will play a pivotal role in defining future clinical
management of the tens of millions of people with type 2 diabetes worldwide."
Additional new data
At the IDF Congress, the ADVANCE investigators also provided important
insights into factors predicting cardiovascular risk in this population.(7)
Age at diagnosis, known duration of diabetes, sex, pulse pressure,
treated hypertension, atrial fibrillation, retinopathy, HBA1C,
albumin/creatinine ratio, and non-HDL cholesterol level at baseline were all
found to be significant predictors of cardiovascular events. A new risk
prediction tool was developed by the ADVANCE investigators using these
variables, paving the way for a new 'risk engine' that may be more relevant
for contemporary populations of treated patients with diabetes compared to
older risk prediction tools such as the Framingham and UKPDS (United Kingdom
Prospective Diabetes Study) models.(7)
Notes to editor:
ADVANCE was designed, conducted, monitored, analyzed, and reported by a
collaborative medical research group supported by the Australian Government's
National Health and Medical Research Council after full peer review. The
study was carried out independently of the industry sponsor, and the
Management Committee-whose membership did not include any industry
representatives-had final responsibility for the reporting of results.
The first part of ADVANCE investigated the effects of intensive blood
pressure lowering on outcome using a fixed combination of perindopril and
indapamide. The results were published in 2007. Reference: ADVANCE
Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, et al. Effects
of a fixed combination of perindopril and indapamide on macrovascular and
microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE
trial): a randomised controlled trial. Lancet. 2007;370:829-840.
The second part of ADVANCE investigated the effects of intensive glucose
control with a gliclazide MR-based regimen and the main results were
published in 2008. These demonstrated that intensive control reduced the
combined major macrovascular and microvascular end point (18.1% vs. 20.0%;
hazard ratio (HR) 0.90; 95% confidence interval 0.82 to 0.98; P=0.013). Major
microvascular events were reduced (9.4% vs. 10.9%; HR 0.86 [0.77 to 0.97];
P=0.014), primarily because of a reduction in nephropathy (4.1% vs. 5.2%; HR
0.79 [0.66 to 0.93], P=0.006), with no significant effect on retinopathy
(P>0.1). Reference: ADVANCE Collaborative Group; Patel A, MacMahon S,
Chalmers J et al. Intensive blood glucose control and vascular outcomes in
patients with type 2 diabetes. NEJM 2008; 358: 2560-2572
The George Institute for International Health is an
internationally-recognized health research organization, undertaking high
impact research across a broad health landscape. It is a leader in the
clinical trials, health policy, and capacity-building areas. The Institute
has a global network of top medical experts in a range of research fields, as
well as expertise in research design, project management, and data and
statistical analysis. With a respected voice among global policy makers, the
Institute has attracted significant funding support from governments,
philanthropic organizations, and corporations. George Institute research is
regularly published in the top tier of academic journals internationally.
The National Health & Medical Research Council of Australia is the
Australian Government's peak body for supporting health and medical research;
for developing health advice for the Australian community, health
professionals, and governments; and for providing advice on ethical behavior
in health care and in the conduct of health and medical research.
The research funding arm of French pharmaceutical company Servier is the
Institut de Recherche International Servier.
References
1. Chalmers J, Zoungas S, Ninomiya T, et al. New results from
ADVANCE. IDF Congress Invited Talk, 22 October 2009. Montreal, Canada.
2. The ADVANCE Collaborative Group. Intensive blood glucose control and
vascular outcomes in patients with type 2 diabetes. N Engl J Med.
2008;358:2560-2572.
3. Turnbull F, Abraira C Anderson R Byington R Chalmers J et
al. Intensive glucose control,and macrovascular outcomes in type 2 diabetes.
Diabetologia, ePub ahead of print, 05 August 2009
4. Schramm TK. Eur Heart J. 2009;30(suppl):304. Abstract ESC
Congress 2009.
5. Khalangot M et al, Diabetes Res Clin Pract. 2009 Sep 29.
[Epub ahead of print]
6. Zoungas S, Patel A, Neal B, et al. ADVANCE-ON: a post-trial
observational study. Oral presentation, IDF Congress, 21 October 2009.
Montreal, Canada.
7. Kengne AP, Patel A, Colagiuri S, et al. Derivation of the
ADVANCE models for predicting the risk of major cardiovascular disease in
people with diabetes. Oral presentation, IDF Congress, 20 October 2009.
Montreal, Canada.
SOURCE: Servier
NEWS 
